- Open Access
MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression
Molecular Cancer volume 14, Article number: 156 (2015)
Migration and invasion enhancer 1 (MIEN1) is a novel gene found to be abundantly expressed in breast tumor tissues and functions as a critical regulator of tumor cell migration and invasion to promote systemic metastases. Previous studies have identified post-translational modifications by isoprenylation at the C-terminal tail of MIEN1 to favor its translocation to the inner leaflet of plasma membrane and its function as a membrane-bound adapter molecule. However, the exact molecular events at the membrane interface activating the MIEN1-driven tumor cell motility are vaguely understood.
MIEN1 was first studied using in-silico analysis on available RNA sequencing data of human breast tissues and its expression was ascertained in breast cells. We performed several assays including co-immunoprecipitation, wound healing, western blotting and immunofluorescence to decipher the molecular events involved in MIEN1-mediated tumor cell migration.
Clinically, MIEN1 is predominantly overexpressed in Her-2 and luminal B subtypes of breast tumors, and its increased expression correlates with poor disease free survival. Molecular studies identified a phosphorylation-dependent activation signal in the immunoreceptor tyrosine based activation motif (ITAM) of MIEN1 and the phosphorylation-deficient MIEN1-mutants (Y39F/50 F) to regulate filopodia generation, migration and invasion. We found that ITAM-phosphorylation of MIEN1 is significantly impaired in isoprenylation-deficient MIEN1 mutants indicating that prenylation of MIEN1 and membrane association is required for cross-phosphorylation of tyrosine residues. Furthermore, we identified MIEN1 as a novel interactor of Annexin A2 (AnxA2), a Ca2+ -dependent phospholipid binding protein, which serves as an extracellular proteolytic center regulating plasmin generation. Fluorescence resonance energy transfer (FRET) confirmed that MIEN1 physically interacts with AnxA2 and functional studies revealed that they mutually cooperate to accentuate tumor cell motility. Interestingly, our study identified that ectopic overexpression of MIEN1 significantly enhances Tyr23-phosphorylation on AnxA2, thereby stimulating cell surface translocation of AnxA2 and catalyzing the activation of its proteolytic activity.
Our data show that the presence and interaction of both MIEN1 and AnxA2 in breast tumors are crucial drivers of cell motility. Our study has now deciphered a novel regulatory network governing the vicious process of breast tumor cell invasion-metastasis, and findings suggest MIEN1-AnxA2 as prospective targets to counter the deadly disease.
Migration and invasion enhancer 1(MIEN1) (also known as C35, C17orf37, RDX12, and MGC14832) is located in the chromosomal region 17q12-21, in the ERBB2 amplicon [1–4]. MIEN1 is frequently amplified along the neighboring genes, ErBB2 and GRB7 in variety of tumors including breast cancer. Our previous studies identified MIEN1 as the prime regulator of cancer cell migration and invasion . In addition, we demonstrated that MIEN1 has a functional isoprenylation ‘CAAX’ motif at the C-terminal tail that is post-translationally modified by geranyl-geranyl transferase-I (GGTase-I) . Prenylated MIEN1 then translocates to the inner leaflet of the plasma membrane and potentiates filopodia formation whereas prenylation-deficient MIEN1-mutants fail to migrate, invade and display reduced metastatic capacity in cancer mouse models. However, the exact molecular events at the membrane interface in MIEN1-driven breast tumor cell motility are poorly understood.
The onset of metastasis depends primarily on the ability of tumor cells to detach from basement membranes by cleaving extracellular matrix proteins and promoting motility and invasion to propel forward [7–11]. One of the key factors regulating the extracellular proteolytic process is the plasmin-plasminogen system; which is composed of a proteolytic cascade comprising the two plasminogen activators- tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) [12–18]. Activation of this proteolytic cascade converts the inactive trypsin-like endopeptidases into potent plasmin, which then cleaves the components of the extracellular matrix proteins thereby facilitating rapid migration and invasion of tumor cells to distant organs.
Here, we report that MIEN1 regulates breast cancer cell migration and invasion in a bifunctional mechanism. We show that MIEN1 has a functional immunoreceptor tyrosine based activation motif (ITAM) cross-phosphorylated at two tyrosine-residues (Y39 and Y50), which is important for triggering downstream signal transduction. In addition, we discovered MIEN1 as a novel interacting partner of Annexin A2, a member of the Annexin family of Ca2+-dependent phospholipid binding proteins [19, 20]. Functional studies confirmed interaction of MIEN1 with AnxA2 at the membrane interface is necessary for activation of plasmin-plasminogen complex, thereby facilitating breast cancer cell migration and invasion. Our study identified a novel regulatory pathway for activating extracellular plasmin generation to promote enhanced breast cancer cell migration and invasion.
MIEN1 is expressed in all subtypes of breast cancer
Enhanced expression of MIEN1 is reported in breast cancer compared to normal breast tissues . Analysis of Cancer Genome Atlas (TCGA) data sets identified significantly elevated MIEN1 expression in different subtypes of breast carcinomas (Apocrine, Large Cell Neuroendocrine, Cribiform, Papillary, Ductal, Lobular, Mixed Ductal and Lobular, Mucinous) patients compared to normal tissues (Fig. 1a). In clinical oncology, evaluations of breast tumors are accompanied by an assessment of the molecular status of ER, PR and Her-2 oncogene. To understand the differential expression of MIEN1 in various subtypes of breast cancer, we examined the expression of MIEN1 within the molecular subtypes of breast cancer. Our findings revealed that MIEN1 is predominantly overexpressed in Her-2 positive (85 % cases with elevated MIEN1) and luminal B (63 % cases with elevated MIEN1) subtypes. However, MIEN1 expression in other subtypes basal-like and luminal A were moderate, whereas majority of the normal breast tissues had low MIEN1 (Fig. 1b). Screening of various established breast tumor lines identified increased expression of MIEN1 in majority of the breast tumor lines (MCF10AT, MCF10CA1a, MCF10CA1d, MCF10CA1h, JIMT-1, BT-474, SKBR-3, MDA-MB231, T47D, MCF-7, MDA-MB436 and HCC-70) compared to the immortalized normal mammary epithelial cell line, MCF10A (Fig. 1c). As expected most of the Her-2 amplified cell lines displayed increased expression of MIEN1 protein (CRL-2330, SKBR-3, and BT-474); but MIEN1 expression is not only restricted to Her-2 amplification indicating its distinct transcriptional and post-translational modifications contributing to its elevated expression in breast tumors. Classification of the patient cohort according to high and low MIEN1 expression using TCGA dataset, confirmed a poor survival in breast cancer patients with elevated MIEN1 expression as previously shown  (Fig. 1d). Altogether, these findings confirm that MIEN1 is a clinically important oncogene, and its increased expression contributes towards an aggressive disease with poor survival.
MIEN1 has a functional ITAM-motif
In addition to isoprenylation motif , MIEN1 harbors several potential phosphorylation sites. Analysis of MIEN1 sequence using computational algorithms (KinasePhos 2.0) identified four potential phosphorylated tyrosine residues (Tyr29, Tyr39, Tyr50 and Tyr85) [22–25] of which Tyr39 and Tyr50 residues are located in the ITAM domain . The canonical ITAM (immunoreceptor tyrosine based activation motif) is an 18 sequence amino acids (YxxI(6–8)YxxL) where tyrosine is separated from a leucine or isoleucine by any two other amino acids, giving the signature YxxL/I; and these two signatures are typically separated by 6 to 8 amino acids. To demonstrate that the Y39/Y50 in the ITAM domain of MIEN1 is phosphorylated, we investigated the phosphorylation status of MIEN1 (Fig. 2a). Immunoprecipitation of GFP-tagged MIEN1 constructs followed by immunoblot analysis using a generic phospho-tyrosine antibody, demonstrated that MIEN1 wild type (MIEN1WT) is tyrosine phosphorylated, whereas the Y39F and Y50F phospho-deficient mutants showed lower phosphorylation status. However Y50F mutant showed a greater loss of phosphorylation compared to Y39F (Fig. 2b). Replacement of Y39 and Y50 with phenylalanine (Y39/Y50F) reduced MIEN1-tyrosine phosphorylation by half; indicating that there is some background phosphorylation on the tyrosine residues outside the ITAM domain.
Since, MIEN1 is also modified by isoprenylation at the C-terminal ‘CVIL’ end responsible for its membrane localization , we investigated whether phosphorylation of ITAM-tyrosine residues is dependent on isoprenylation. For this, we analyzed the tyrosine-phosphorylation status of MIEN1 in NIH3T3 cells (with low endogenous MIEN1) transfected with GFP vector only, MIEN1WT or prenylation-deficient MIEN1C112S constructs. In addition, the MIEN1WT expressing cells were either treated with a pharmacological inhibitor against GGTase enzyme GGTI (geranylgeranyl transferase I inhibitor) or vehicle control (DMSO). MIEN1WT expressing cells showed robust tyrosine-phosphorylation whereas GGTI treatment severely abrogated the effect similar to the MIEN1C112S expressing cells (Fig. 2c). These data indicate that tyrosine-phosphorylation of MIEN1 in the ITAM-domain is dependent on prior isoprenylation. These results demonstrate that correct localization of the protein to the plasma membrane is required for subsequent post-translational modification via tyrosine-phosphorylation at the ITAM-domain.
Relative importance of ITAM and CAAX motifs in MIEN1- induced migration
Next, we evaluated the functional impact of MIEN1-ITAM and isoprenyl mutants compared to the wild-type protein (MIEN1WT). For this, we stably expressed MIEN1 constructs in NIH3T3-cells with low endogenous protein. Cell migration was significantly enhanced in cells expressing MIEN1WT relative to the vector control (Fig. 3a, b), whereas MIEN1C112S failed to migrate into the wound (Fig. 3c), as reported earlier . Similar to the isoprenyl-mutants, NIH3T3 expressing ITAM mutants had a reduced migratory potential (Fig. 3d–f). However, we did not observe significant differences in functional contribution between individual tyrosine mutants (MIEN1Y39F and MIEN1Y50F) compared to MIEN1Y39/50F confirming that the phosphorylation of both tyrosine residues is vital for ITAM induced functions or signaling events to mediate cell migration. The MIEN1Y39/50F/C112S cells did not show any additive effect suggesting both isoprenylation and ITAM-phosphorylation are important for MIEN1 function (Fig. 3g). To determine whether MIEN1 posttranslational modifications are also required for invasive function, we performed matrigel invasive assays with MDA-MB231 cells transfected with MIEN1 constructs. Consistent with the data from the migration assays, MIEN1WT expression increased the invasive potential of breast cancer cells whereas ITAM and isoprenyl mutants failed to show an invasive phenotype (Additional file 1: Figure S1).
Cell migration is the result of coordination between membrane protrusive structures at a leading edge, adhesion and de-adhesion followed by translocation of the cell body in the direction of migration. In migrating cells, protrusive structures such as filopodia are the pioneers, which probe the environment for cues and guide cell migration. MIEN1 has been shown to induce filopodia formation and mutation of the isoprenyl motif impaired this function . Here we inquired whether the ITAM regulates MIEN1-induced filopodia, aside from the isoprenyl motif. NIH3T3 cells expressing various constructs of MIEN1 were stained with rhodamine-conjugated phalloidin and subjected to immunofluorescence analysis post wound induction. Stable expression of MIEN1 in NIH3T3 cells visibly increased the number and length of filopodia post wound induction compared to MIEN1-mutants expressing cells (Fig. 3i–n) confirming that ITAM and CAAX are important for MIEN1 function. Immunoblotting analysis of cells expressing vector control and MIEN1 constructs confirmed the equal expression of the wild type and mutants MIEN1 protein (Fig. 3o).
MIEN1 is an interactor of AnxA2
We investigated the potential interacting partners of MIEN1 to define the mechanisms associated with tumor cell migration and invasion. In a yeast two-hybrid assay, we identified MIEN1 as potential interactor of AnxA2, a Ca(2+)-dependent phospholipid binding protein which translocates to the cell surface upon cellular signaling. Full-length AnxA2 cDNA cloned into GAL4 DNA-binding domain (GAL4 DNA-BD) of vector pGBKT7 was found to interact with MIEN1 in a yeast two-hybrid screen from a transformed human placental cDNA library as bait. Positive clones were selected on high-stringency medium (synthetic dropout medium) selection markers SD/−Ade/−His/−Leu/−Trp/X-α-gal, and only true interactor-MIEN1 could activate the expression of β-galactosidase (blue color). The left panel shows positive interaction of MIEN1 with AnxA2, but not with p53. The right panel shows the positive control p53 − T-antigen interaction, while the AnxA2 − p53 interaction served as the negative control (Fig. 4a). Following immunoblotting and real-time PCR analysis of breast cell lines expressing both MIEN1 and AnxA2 (Additional file 2: Figure S2A-B), we performed co-immunoprecipitation of endogenous AnxA2 with MIEN1 in BT-474 cells to confirm the yeast two-hybrid data. The reciprocal immunoprecipitation of MIEN1 also pulled down endogenous AnxA2, confirming that these two proteins indeed reside in a complex. The total input used for the immunoprecipitation confirmed equal loading and similar levels of expression of both the proteins (Fig. 4b). Colocalization experiments using confocal microscopy also confirmed interaction of endogenous AnxA2 and MIEN1 primarily in the cytosol, plasma membrane and the perinuclear area of breast cancer cells (Fig. 4c). Finally to confirm that AnxA2 and MIEN1 physically interact intracellularly, we performed FRET detection by fluorescence lifetime imaging microscopy (FLIM) assay to measure the proximity of MIEN1 and AnxA2. The lifetime decays of the donor (MIEN1) and donor-acceptor (MIEN1-AnxA2) pair were measured to be 1.75 and 1.26 ns, respectively. Substituting the lifetime values in the Förster equation, the efficiency of energy transfer was determined to be 28 %, which corresponds to a distance of 50.3 Å between the donor and acceptor pair; indicating that MIEN1 and AnxA2 indeed physically interact and reside in a very close proximity (Fig. 4d). These studies clearly validate MIEN1 as a novel interactor of AnxA2.
MIEN1 enhances AnxA2 phosphorylation to promote cell surface translocation and breast cancer cell migration
We investigated the effects of MIEN1 and AnxA2 interaction on cell migration, given their independent implications in cell migration and invasion (Fig. 5a-c). We silenced MIEN1 and AnxA2 alone or in combination (Fig. 5b) and examined the effects on motility of MDA-MB231 cells. In monolayer migration assays, the wound closure of cells with MIEN1 knockdown was significantly inhibited compared to siGFP (control) transfected MDA-MB231 cells (Fig. 5a, Additional file 3: Figure S3A-B). Silencing of AnxA2 resulted in impairment of cell motility at 6 and 12 h following wound creation (Fig. 5a, Additional file 3: Figure S3A-B). Using similar knockdown strategy, we observed that dual depletion of MIEN1 and AnxA2 led to a two-fold decrease compared to siGFP (Fig. 5c), indicating that MIEN1 and AnxA2 functionally cooperate to promote breast cancer cell migration. AnxA2 is a phospholipid binding protein localizing to the plasma membrane towards the cytosolic side. Previous studies proved that the phosphorylation of AnxA2 at the Y23 residue in the N-terminus of the protein causes its translocation to the extracellular surface, thereby activating extracellular proteolysis [26, 27]. To verify whether MIEN1 expression affects AnxA2 phosphorylation and subsequent translocation to the extracellular surface, we performed immunoblotting analysis followed by total internal reflection microscopy (TIRF-M). As shown in Fig. 5d, over-expression of MIEN1 enhanced AnxA2 phosphorylation at Y23. Conversely, down-regulation of MIEN1 led to a decreased phosphorylation of AnxA2 at Y23 (Fig. 5e). To further confirm this observation, we performed total internal reflection fluorescence microscopy (TIRF-M) in MDA-MB231 cells. Stable MDA-MB231 cells expressing vector control or MIEN1WT were probed with AnxA2 and phospho-AnxA2Tyr23 antibodies followed by TIRF microscopy to determine cell surface total-AnxA2 and phospho-AnxA2. MIEN1 overexpression significantly enhanced phosphorylation of AnxA2 at the tyrosine 23 residue and subsequently cell surface localized AnxA2 levels; indicating MIEN1 dependent signaling and interaction activate AnxA2 function (Fig. 5f).
MIEN1 activates AnxA2 dependent extracellular proteolytic functions
Extracellular surface localized AnxA2 functions as a receptor for tPA and plasminogen; by binding to both enzymes, and catalytically activating plasmin generation [28, 29]. Increased levels of plasmin enhance proteolytic cleavage of ECM thus allowing cancer cells to migrate and invade to distant sites. To confirm that MIEN1 regulates AnxA2 dependent plasmin generation, we investigated the effects of MIEN1 ablation either alone or in combination with AnxA2 plasmin generation in breast cancer cells. Using basal-like HCC70 and luminal MCF7 cells (these two lines express high levels of both AnxA2 and MIEN1), we inquired whether the interaction of MIEN1 and AnxA2 had an effect on plasmin generation. We first confirmed siRNA-mediated knockdown of MIEN1 and AnxA2 in HCC-70 and MCF-7 (Fig. 6a, c) respectively. Western blotting analysis confirmed that the expression of MIEN1 or AnxA2 was dramatically reduced in the cells upon transfection with either MIEN1 or AnxA2 siRNA. Next, we examined the biochemical conversion of plasminogen to plasmin in both cell lines upon siRNA treatment. Silencing of both MIEN1 and AnxA2 led to a significant decrease in plasmin levels in both HCC-70 and MCF-7 (P < 0.05) (Fig. 6b, d). While the knockdown of AnxA2 led to a decrease in plasminogen conversion to plasmin in the initial hours as previously shown , the total change in plasmin levels were insignificant compared to the control siRNA treated cells. Interestingly, suppression of MIEN1 in MCF-7 cells led to approximately 1.7 fold decrease in plasmin levels but not in HCC-70; a difference which can be attributed to the expression of various regulators of the plasminogen-plasmin system. Taken together, these data indicate that co-expression of both AnxA2 and MIEN1 enhance plasmin generation and lead to an increase in breast tumor cell migration and invasion which in turn drive the metastatic process.
Cell motility process is a highly coordinated event integrated by extensive transient signaling networks of proteins [31, 32]. Protein–protein interactions are the underlying backbone of migratory processes including actin structures, proteolytic enzymes that degrade the ECM and the coordination between detachment/re-adhesion cycles . Here we report the dynamics of MIEN1-induced signaling that regulate tumor cell migration and invasion.
MIEN1 expression is significantly increased in breast cancer cells and analysis of TCGA database showed that elevated expression of MIEN1 correlates with poor survival of breast cancer patients. Several post-translational modifications regulate MIEN1 protein functions and downstream signaling events. In addition to isoprenylation, in this study we identified that phosphorylation of tyrosine residues (Y39 and Y50) in the ITAM motif is important for its function. Signal transduction by ITAM is initiated by the phosphorylation of the tyrosine residues within the ITAM sequence, followed by the recruitment of members of the Syk kinase family [34–36]. The binding of Syk to the phosphorylated-ITAM results in the activation of multiple signaling cascades. Previous studies indicated that Syk kinase potentiates MIEN1 dependent signaling in breast tumor cells . Using phospho-deficient single or double mutants, we show that MIEN1 is tyrosine phosphorylated in the ITAM motif. In addition, we also demonstrate that isoprenylation and membrane localization is important for ITAM-phosphorylation. Blocking isoprenylation of MIEN1 using GGTase inhibitors or genetic mutation of the ‘CVIL’ prenylation domain significantly impairs ITAM-or tyrosine phosphorylation. These findings indicate that ITAM-dependent signal transduction by MIEN1 depends on prior isoprenylation and correct localization of the protein to the inner leaflet of plasma membrane. As expected, ITAM phosphorylation was also important for MIEN1-dependent migration and invasion as phospho-deficient MIEN1 mutants severely impaired breast cancer cell migration and invasion.
Interestingly, we identified MIEN1 as an important interactor of AnxA2. A multifunctional protein, AnxA2 is involved in various cellular activities and its dysregulation is implicated in multiple diseases including breast cancer . Although, AnxA2 is predominantly a cytosolic protein, phosphorylation on its N-terminal Y23 translocates the protein to the cell surface [38, 39]. Cell surface AnxA2 interacts with plasminogen and tPA and mediates the conversion of plasminogen to plasmin . In breast cancer, AnxA2 mediated plasmin activation is shown to be essential for angiogenesis, migration and invasion which are critical events in disease metastasis.
Our data provide evidence that MIEN1 interaction with AnxA2 enhances Y23 phosphorylation of AnxA2 and subsequent translocation of the protein to the cell surface leads to increased plasmin levels which support breast tumor cell motility. Although, MIEN1 does not have a kinase domain, we believe this phosphorylation on AnxA2 is a downstream signaling event regulated by MIEN1.
Our studies convincingly demonstrate that interaction of MIEN1 with AnxA2 is required for extracellular plasmin generation thereby increasing breast cancer cell migration and invasion. Our findings place MIEN1 and anxA2 as attractive therapeutic targets for blocking invasive cancers.
Materials and methods
In silico analysis
MIEN1 was first studied using in-silico analysis on available DNA microarray and RNA sequencing data of breast tumors and normal tissues from TCGA website (http://cancergenome.nih.gov/) and the bc-GenExMiner database v3.1 (http://bcgenex.centregauducheau.fr/BC-GEM/GEM_Accueil.php?js=1). The breast cancer gene-expression Miner v3.1 was utilized to assess MIEN1 expression in breast cancer molecular subtypes. Bc-GenEXMiner analyzes available gene expression data sets from repositories such as Gene Expression Omnibus (GEO), Array Express and Stanford microarray database [41–43]. The analysis was performed through a built-in robust single sample predictor (SSP) classification (RSSPC), which includes intersection of three SSPs . The UCSC Cancer Genomics Browser can be accessed through https://genome-cancer.ucsc.edu/ and following the central hyperlink. The UCSC Cancer Genomics Browser displays the genomic, clinical and annotation data in multiple views [45–50]. We used the breast cancer gene expression (BRCA) (IlluminaHiSeq) dataset followed by subgrouping for C17orf37 (MIEN1) expression. Subgroups allow users to group samples according to an arbitrary combination of annotation data values. We stratified the BRCA dataset according to MIEN1 expression: low (green from 0.0 to −6.67) and high (red from 1.0 to 6.34) followed by Kaplan Meier plot to generate the survival percentage over time (days) with respect to MIEN1 expression.
GFP-MIEN1 (MIEN1WT) was generated by PCR amplification of full-length human MIEN1 cDNA (347 base pairs) and directionally cloned into pEGFP-C1 vector as previously described [5, 6]. GFP-MIEN1 mutants were generated using QuikChange multi-site-directed mutagenesis kit from Stratagene (La Jolla, CA, USA) from the GFP-MIEN1WT template.
MIEN1 and AnxA2 small interfering RNA transfection in breast cancer cells
Human MIEN1 smart pool siRNA and AnxA2 smart pool siRNA were used for knock-down experiments (Dharmacon, Lafayette, CO). Green fluorescent protein (GFP) siRNA (Qiagen, Germatown, MD) served as control. Breast cancer cells were transfected with siRNA duplex at a concentration of 40 nM using Lipofectamine RNAiMAX purchased from Invitrogen (Grand Island, NY, USA).
Cell lines and culture conditions
NIH3T3 mouse fibroblast cells and human breast cancer cell lines (SKBR-3, BT-474, MDA-MB231, MDA-MB4-36, HCC-70, HCC-1937, MCF-7, T47D) were obtained from American type culture collection. MCF10A, MCF10AT, MCF10CA1a, MCF10CA1d, MCF10CA1h cells were obtained from Karmanos cancer center, and JIMT-1 from Leibniz-Institut DSMZ. All cell lines were maintained in a humidified incubator containing 5 % CO2/95 % air at 37 °C. Stable NIH3T3 and MDA-MB231 cells expressing GFP-MIEN1 constructs were generated using 500 μg/ml and 650 μg/ml G418 antibiotic (Invitrogen).
Yeast two-hybrid screening
A yeast two-hybrid screening was carried out as described previously. Full-length human AnxA2 cDNA (GenBank entry NM_004039) fragment was cloned into pGBKT7 vector (Clontech). The recombinant plasmid used was GAL4 DNA binding bait (DNA-BD/bait) and transformed into AH109 yeast cells screened for growth on synthetic dropout (SD/-Trp) medium. A human placental pre-transformed cDNA library (Clontech) was used for screening interacting proteins. This library was made using the recombinant vector pGADT7, which contains the activation domain (DNA-Ac/library) with a different nutrient marker -Leu and was transformed into strain Y187 and screened for growth on SD/-Leu medium. The interaction screening was conducted by mating the DNA-BD/ bait strain and DNA-Ac/library strain, and the positive clones were selected. Positive clones were selected on high-stringency medium with selection markers SD/-Ade/-His/-Leu/-Trp/ X-R-gal and then screened as described above (Clontech). Positive yeast clones were selected by prototrophy for histidine or expression of β-galactosidase and then subjected to sequence analysis to search for novel interacting proteins.
FLIM based forster resonance energy transfer (FRET) assay
FRET was performed as described previously with minor modifications . Briefly, cells were immunostained for MIEN1 and AnxA2, labeled with donor Alexa-488 and acceptor fluorophore Alexa-594, respectively. Upon transfer of energy from the donor to the acceptor, the donor fluorophore’s lifetime was monitored as an indicator for the presence or absence of FRET.
Determination of the förster distance (R0)
The transfer efficiency was assessed from the donor (D) and the donor in the presence of the acceptor (D + A) lifetimes using the equation below
Using the transfer efficiency, E (0.28) and the transfer distance, R0 (43 Aο), the distance between the two molecules was determined to be 50.3Aο
Immnunoprecipitation and immunoblotting assays
Immunoprecipitation and immunoblotting were performed as described previously . In brief cells were lysed with NP-40 lysis buffer supplemented with protease and phosphatase inhibitor cocktail (Millipore, Billerica, MA). The supernatants were taken as the total cell lysates; and using protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA), AnxA2 and MIEN1 were immunoprecipitated. The immunoprecipitated proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes for immunoblotting. The antibodies used were MIEN1 from Abnova (Taipei, Taiwan), AnxA2 (Santa Cruz Biotechnology) and β-actin (Santa Cruz Biotechnology)
Migration and invasion assay
Cells were grown in a monolayer and upon reaching confluence, the cell layer was scratched using a sterile micropipette tip. The wound was imaged at the indicated time points following wound creation. Representative images were captured and analyzed using Image J software. Invasion assays were performed using HTS FluoroBlok multi well insert system from BD Falcon, (San Jose, CA, USA) as previously described .
Cells were fixed using 4 % paraformaldehyde (Affymetrix, Santa Clara, CA, USA) and stained with rhodamine-conjugated phalloidin, MIEN1 and AnxA2 primary antibodies followed by Alexa Fluor 488 and 594 secondary antibodies (Invitrogen). Cells were mounted on glass coverslips with Prolong Gold mounting medium (Invitrogen). Confocal images were acquired using Zeiss confocal microscope LSM510.
Total internal reflection fluorescence (TIRF) microscopy
For TIRF microscopy, MDA-MB231 cells were grown on coverslips and then transfected with empty vector or GFP-MIEN1 wild type. The cells were fixed with 4 % paraformaldehyde, permeabilized with 0.1 % Triton X-100, washed with PBS and blocked with BSA. Cells were subsequently treated with AnxA2 (BD Biosciences) and phospho-AnxA2 Tyr23 (Santa Cruz Biotechnology) antibodies followed by AlexaFlour 488 conjugated secondary antibody and mounted with Permafluor mounting medium. For TIRF images, the cells were visualized on an Olympus IX71 microscope with commercial TIRF attachment as described previously by 60 × oil immersion objective .
Plasminogen activation assays
The assay was performed according to the previously established protocols . In brief, HCC-70 and MCF-7 cells were transfected with GFP, MIEN1 and/or AnxA2 siRNA. Cells were then incubated with recombinant 10 nM human tPA and 100 nM Glu-plasminogen and subsequently treated with the fluorogenic plasmin substrate, D-VLK-AMC (D-Val-Leu-Lys-7-amido-4-methylcoumarin; Sigma). Substrate hydrolysis was measured for 12 h. Results were obtained as fluorescence units (FUs) using a fluorescence spectrophotometer (380 nm excitation and 460 nm emission wavelengths).
Data acquired from migration, invasion, immunofluorescence and plasmin generation assays were analyzed using student t-test. The statistical analysis was performed using Windows version of SPSS along with GraphPad Prism 4.02 software. The ImageJ software was used for wound healing assay analysis. Significance was defined as *P < 0.05, **P < 0.01, ***P < 0.001 compared to controls and between different treatment groups.
Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol. 2003;163:1979–84.
Evans EE, Henn AD, Jonason A, Paris MJ, Schiffhauer LM, Borrello MA, et al. C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Mol Cancer Ther. 2006;5:2919–30.
Deblois G, Chahrour G, Perry MC, Sylvain-Drolet G, Muller WJ, Giguere V. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis. Cancer Res. 2010;70:10277–87.
Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A, et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2010;12:R25.
Dasgupta S, Wasson LM, Rauniyar N, Prokai L, Borejdo J, Vishwanatha JK. Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene. 2009;28:2860–72.
Dasgupta S, Cushman I, Kpetemey M, Casey PJ, Vishwanatha JK. Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis. J Biol Chem. 2011;286:25935–46.
Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol. 2008;3:221–47.
Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett. 2009;284:122–30.
Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol. 2009;185:11–9.
Palmer TD, Ashby WJ, Lewis JD, Zijlstra A. Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev. 2011;63:568–81.
Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci. 2013;34:283–9.
Zhou HM, Nichols A, Meda P, Vassalli JD. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J. 2000;19:4817–26.
Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25–40.
Andronicos NM, Ranson M. The topology of plasminogen binding and activation on the surface of human breast cancer cells. Br J Cancer. 2001;85:909–16.
Ranson M, Andronicos NM. Plasminogen binding and cancer: promises and pitfalls. Front Biosci. 2003;8:s294–304.
Palumbo JS, Talmage KE, Liu H, La Jeunesse CM, Witte DP, Degen JL. Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. Blood. 2003;102:2819–27.
Deryugina EI, Quigley JP. Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol. 2012;2012:564259.
Paoletti C, Hayes DF. Molecular testing in breast cancer. Annu Rev Med. 2014;65:95–110.
Grewal T, Enrich C. Annexins — Modulators of EGF receptor signalling and trafficking. Cell Signal. 2009;21:847–58.
Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. Int J Mol Sci. 2013;14:6259–305.
Katz E, Dubois-Marshall S, Sims AH, Faratian D, Li J, Smith ES, et al. A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk. Br J Cancer. 2010;103:401–10.
Wong YH, Lee TY, Liang HK, Huang CM, Wang TY, Yang YH, et al. KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. Nucleic Acids Res. 2007;35:W588–594.
Shen HB, Chou KC. QuatIdent: a web server for identifying protein quaternary structural attribute by fusing functional domain and sequential evolution information. J Proteome Res. 2009;8:1577–84.
Safaei J, Manuch J, Gupta A, Stacho L, Pelech S. Prediction of 492 human protein kinase substrate specificities. Proteome Sci. 2011;9 Suppl 1:S6.
Dinkel H, Van Roey K, Michael S, Davey NE, Weatheritt RJ, Born D, et al. The eukaryotic linear motif resource ELM: 10 years and counting. Nucleic Acids Res. 2014;42:D259–266.
Valapala M, Thamake SI, Vishwanatha JK. A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. J Cell Sci. 2011;124:1453–64.
Valapala M, Maji S, Borejdo J, Vishwanatha JK. Cell surface translocation of annexin A2 facilitates glutamate-induced extracellular proteolysis. J Biol Chem. 2014;289:15915–26.
Flood EC, Hajjar KA. The annexin A2 system and vascular homeostasis. Vasc Pharmacol. 2011;54:59–67.
Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR, et al. Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci. 2011;31:14346–60.
Sharma M, Ownbey RT, Sharma MC. Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol. 2010;88:278–86.
Stupack DG, Cho SY, Klemke RL. Molecular signaling mechanisms of cell migration and invasion. Immunol Res. 2000;21:83–8.
Vicente-Manzanares M, Horwitz AR. Cell migration: an overview. Methods Mol Biol. 2011;769:1–24.
Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003;112:453–65.
Underhill DM, Goodridge HS. The many faces of ITAMs. Trends Immunol. 2007;28:66–73.
Hirose M, Kitano J, Nakajima Y, Moriyoshi K, Yanagi S, Yamamura H, et al. Phosphorylation and recruitment of Syk by immunoreceptor tyrosine-based activation motif-based phosphorylation of tamalin. J Biol Chem. 2004;279:32308–15.
Fueller F, Kubatzky KF. The small GTPase RhoH is an atypical regulator of haematopoietic cells. Cell Commun Signal. 2008;6:6.
Zhang F, Liu Y, Wang Z, Sun X, Yuan J, Wang T, et al. A novel Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level. Mol Cell Endocrinol. 2015;411:75–85.
Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem. 2004;279:43411–8.
Valapala M, Vishwanatha JK. Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem. 2011;286:30911–25.
Dutta S, Bandyopadhyay C, Bottero V, Veettil MV, Wilson L, Pins MR, et al. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration. Mol Oncol. 2014;8:483–507.
Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G, et al. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 2012;131:765–75.
Jezequel P, Frenel JS, Campion L, Guerin-Charbonnel C, Gouraud W, Ricolleau G, et al. bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database (Oxford). 2013;2013:bas060.
Jezequel P, Juin PP, Campone M. [<< Bioinfomics >>: a new research field]. Bull Cancer. 2014;101:118–9.
Weigelt B, Mackay A, A’Hern R, Natrajan R, Tan DS, Dowsett M, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010;11:339–49.
Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, et al. The UCSC Cancer Genomics Browser. Nat Methods. 2009;6:239–40.
Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010;26:i237–245.
Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, et al. The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Res. 2011;39:D951–959.
Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep. 2013;3:2652.
Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, et al. The UCSC Cancer Genomics Browser: update 2013. Nucleic Acids Res. 2013;41:D949–954.
Goldman M, Craft B, Swatloski T, Cline M, Morozova O, Diekhans M, et al. The UCSC Cancer Genomics Browser: update 2015. Nucleic Acids Res. 2015;43:D812–817.
Das S, Shetty P, Valapala M, Dasgupta S, Gryczynski Z, Vishwanatha JK. Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of annexin A2 in prostate cancer cells. Biochemistry. 2010;49:2216–26.
We would like to thank the microscopy core facility at the Center for Commercialization of Fluorescent Technologies at University of North Texas Health Science Center for their help. We also extend our gratitude to Dr. Irina Akapova for her help on the FRET studies.
This work was supported in part by National Institute on Minority Health and Health disparities Grant 1P20 MD006882 to JKV.
The authors declare that they have no competing interests.
MK and SD conceived the manuscript and the experimental protocols. MK, SD, SR and SD performed the molecular studies. LG extracted the bc-GenExMiner database data. PKS performed cell culture. ZG assisted with FLIM based Forster resonance energy transfer (FRET) studies. MK and SD prepared and finalized the manuscript. JV acquired funding and gave substantial contribution to conception and study design and in data interpretation as well as critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.
Marilyne Kpetemey and Subhamoy Dasgupta contributed equally to this work.
Posttranslational modifications on MIEN1 regulate its invasion function. (A-G) MDA-MB231 transfected cells were prelabeled with calcein AM fluorescent dye and an invasion assay was performed with 10 % serum as a chemoattractant in the lower chamber. The fold change of invasion was normalized to GFP (empty vector) transfected cells and expressed as the means ± S.E. of three independent experiments (O). (TIFF 11758 kb)
Expression of MIEN1 and AnxA2 in a panel of breast cell lines. (A) The protein expressions of MIEN1 and AnxA2 were analyzed by immunoblotting analysis. (B) Quantitative real time PCR showed the mRNA expressions of MIEN1 and AnxA2 in breast cell lines. (JPEG 342 kb)
MIEN1 and AnxA2 are required for MDA-MB231 cell migration. MDA-MB231 cells were treated with AnxA2 or/and MIEN1 siRNA/GFP siRNA for 72 h. Scratch was made using a pipet tip in MDA-MB231 cells confluent monolayer and healing of the wound was monitored. (A) Representative images were acquired at 0 and 6 h. (B) Graph shows the percent wound closure at 6 h intervals after wound formation. (JPEG 913 kb)
About this article
Cite this article
Kpetemey, M., Dasgupta, S., Rajendiran, S. et al. MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression. Mol Cancer 14, 156 (2015). https://doi.org/10.1186/s12943-015-0428-8
- Annexin A2
- Breast cancer